대한한의학회지 (The Journal of Korean Medicine)
- 제25권4호
- /
- Pages.129-138
- /
- 2004
- /
- 1010-0695(pISSN)
- /
- 2288-3339(eISSN)
A Pilot Study to Assess the Effect of Gami-Jiwhang-Tang on Cognitive Effects in Healthy Children
-
Bahn Geon-Ho
(Department of Psychiatry, Kyung Hee University School of Medicine) ;
-
Kim Chang-Ju
(Subdivision of Child & Adolescent Psychiatry, Department of Physiology, Kyung Hee University School of Medicine) ;
-
Chung Joo-Ho
(Department of Pharmacology, Kyung Hee University School of Medicine) ;
- Kim Yong-Hee (Department of Psychiatry, Kyung Hee University School of Medicine) ;
- Paik Eun-Kyung (Haema Oriental Medical Clinic) ;
- Park Jae-Hyung (Haema Oriental Medical Clinic)
- 발행 : 2004.12.01
초록
Objective : Treatments for patients with mental retardation and pervasive developmental disorders are not curative, and are designed to help those with disabilities adjust to their environments and daily demands. As clinicians, the present authors tried to find agents with potentially curative properties. Among the numerous herbal formulations available, we chose and assessed Gami-jiwhang-tang (GJT) in the hope that it would improve cognitive development of children. Methods : Subjects were typically-developing healthy, 7- to 8-year-old boys and girls living in Seoul, Korea. The experimental group took GJT for six weeks and was followed up six weeks after discontinuation of GJT. The control group was assessed at the same intervals but did not receive placebos. To measure the effects of GJT, neuropsychological tests and intelligence test were taken before commencing GJT and twelve weeks later. Resulets and Conclusion : For all of the ANOVAs, the treatment by time interaction terms was not significant. However, the experimental group showed the tendency to be progressed in most subscales compared with the control group, especially on performance intelligence, visual organization, and verbal fluency. Conclusion : Although GJT failed to reveal significant improvement in cognition, we remain hopeful about the compound and believe that it should be evaluated by a double-blind, placebo-controlled trial in the future.